
Valued at a market cap of $9.2 billion, Tempus AI (TEM) stock went public in June 2024. Since its initial public offering, TEM stock has returned over 35% to shareholders. However, the stock fell close to 20% on May 28 after Spruce Point Capital initiated a short position in the artificial intelligence company.
Tempus AI is a Chicago-based healthcare technology company that provides genetic sequencing, molecular testing, and diagnostic services to healthcare providers. It offers data analytics platforms, clinical trial matching services, and algorithmic tests in oncology. Tempus AI aims to leverage artificial intelligence to advance precision medicine and the development of cancer treatments.